Trial Profile
A prospective, observational study assessing the efficacy of iron chelation to counteract the effects of iron overload in lower-risk myelodysplastic syndrome patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Deferiprone (Primary) ; Deferoxamine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results (Data cut off July 21, 2016; n=768), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology